drugset / Trial / NCT00611403

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

NCT00611403

Phase 2 Completed 137 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and efficacy of cyclosporine ophthalmic emulsion administered twice daily following LASIK surgery

Timeline

Start
2007-12
Primary completion
2008-12
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Castor Oil Unknown Other
Comparator Cyclosporine Peptide 0.05 % Other

Indications